EirGenix, Inc. has announced positive results from a Phase III clinical trial for its trastuzumab biosimilar version of Herceptin, EG12014, as the proposed breast cancer biosimilar has met its primary endpoint.
EirGenix Makes Progress With Trastuzumab Biosimilar
Company Plans To Submit Filings To Both FDA and EMA
Taiwan’s EirGenix has made progress with its trastuzumab biosimilar for breast cancer, EG12014, announcing positive Phase III clinical results for the Herceptin equivalent.
More from Biosimilars
While Amneal cannot wait to jump into unexplored biologics space, it wants to channel its GLP-1 power into the Metsera partnership and service big pharma, and less so on its own generics.
Hungary’s Gedeon Richter and its Japanese partner Mochida have together unveiled plans to file their proposed Actemra/RoActemra biosimilar with major regulators, after biosimilar competition to the IL-6 receptor inhibitor materialized in the US last year.
As Bob Bradway addressed the J.P. Morgan Healthcare Conference in San Francisco, the Amgen chief executive discussed the firm’s biosimilars business – including an ocrelizumab rival to Ocrevus that has just been added to its pipeline. Meanwhile, the CEO also outlined his expectations for imminent biosimilar competition to Amgen’s Prolia and Xgeva denosumab brands.
More from Products
Partners Fresenius and Formycon have racked up another pair of approvals for their Otulfi ustekinumab biosimilar rival to Stelara, this time in the UK and Canada.
At the 2025 J.P. Morgan Healthcare Conference, Johnson & Johnson outlined a new competition blueprint for anti-inflammatory biosimilars, going beyond the next blockbuster Tremfya.
In an exclusive interview with Generics Bulletin, Aspargo Labs CEO Michael Demurjian discusses the importance of reformulated liquid oral suspension drugs, while outlining plans to launch a smart device that connects patients and doctors.